AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This approval is specifically for patients whose tumors exhibit exon 19 deletions or […]
AstraZeneca lung cancer drug Tagrisso (osimertinib) for the treatment of non-small cell lung cancer (NSCLC) in a first line setting has been granted the breakthrough therapy designation by the by the US Food and Drug Administration.
AstraZeneca has achieved a significant milestone with its lung cancer drug, Tagrisso (osimertinib), which has recently been granted the Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the first-line treatment of non-small cell lung cancer (NSCLC). This designation is specifically for treating metastatic NSCLC patients who have tested positive for […]